Table 1

Comparison of performance among authoritative cancer-associated VTE RAMs in guidelines in medical patients with lung cancer

RAMsItemsScoreHigh riskBe validated in ambulatory patients with lung cancerBe validated in inpatients with lung cancer
KhoranaCancer siteScore ≥3NoNo
Very high-risk site (stomach, pancreas)2
High-risk site (lung, lymphoma, gynaecologic, bladder, testicular)1
Platelet count ≥350×109/L1
Haemoglobin <100 g/L and/or use of ESA1
Leucocyte count >11×109/L1
BMI ≥35 kg/m21
ViennaKhorana scoreScore ≥3UnknownUnknown
D-dimer ≥1.44 μg/mL1
Soluble P-selectin ≥53.1 ng/mL1
PROTECHTKhorana scoreScore ≥3NoNo
Gemcitabine chemotherapy1
Platinum-based chemotherapy1
CONKOKhorana score with BMI ≥35 kg/m2 being replaced with ECOG PS ≥21Score ≥3NoNo
ONKOTEVKhorana score >21Score ≥2UnknownYes
Metastatic disease1
Previous VTE1
Vascular/lymphatic macroscopic compression1
COMPASS-CATAnthracycline treatment6Score ≥7YesNo
Time since cancer diagnosis ≤6 months4
CVC3
Advanced stage of cancer2
Cardiovascular risk factors5
Hospitalisation for acute medical illness2
A history of VTE1
Platelet count ≥350×109/L2
Tic-OncoBMI >25 kg/m2Not mentioned≥point which maximises the Youden indexUnknownUnknown
Family history
Cancer site
HR
VHR
Cancer stage
GRS
rs2232698
rs6025
rs5985
rs4524
CATS/MICACancer siteNomogramScore ≥110UnknownNo
D-dimer
  • BMI, body mass index; CVC, central venous catheter; ECOG, Eastern Cooperative Oncology Group; ESA, erythropoiesis-stimulating agent; GRS, genetic risk score; HR, high risk; RAMs, risk assessment models; VHR, very high risk; VTE, venous thromboembolism.